Core Insights - Can-Fite BioPharma Ltd. has raised $175 million in funding to advance its lead drug candidates, Namodenoson and Piclidenoson, into pivotal Phase III studies for liver cancer and psoriasis respectively [1][6] Group 1: Company Overview - Can-Fite is a biotechnology company focused on developing small-molecule drugs targeting oncological and inflammatory diseases, specifically through the A3 adenosine receptor (A3AR) [2][6] - The company is currently conducting pivotal Phase III trials for Namodenoson in advanced liver cancer and Piclidenoson in moderate-to-severe psoriasis [2][6] Group 2: Drug Development and Trials - Namodenoson has shown selective targeting of liver and pancreatic tumor cells while sparing healthy tissue, and is currently enrolling patients for its Phase III study [2][3] - Piclidenoson is also in a pivotal Phase III trial for psoriasis, with both candidates demonstrating favorable safety profiles and promising efficacy in previous Phase II trials [3][4] Group 3: Funding and Commercialization - The cumulative funding has supported drug manufacturing, regulatory activities with the FDA and EMA, and the development of a broad patent portfolio [3] - Can-Fite has signed seven commercialization agreements with strategic partners for future marketing of its drug candidates upon regulatory approval [5] Group 4: Future Prospects - The company is also conducting a Phase IIa study of Namodenoson in pancreatic cancer and a Phase IIb trial in metabolic dysfunction-associated steatohepatitis (MASH) [4][6] - Namodenoson has received Orphan Drug Designation in the U.S. and Europe and Fast Track Designation for hepatocellular carcinoma by the FDA [6]